Sofosbuvir-Daclatasvir Is Suboptimal in Patients with Genotype 2 Chronic Hepatitis C Infection: Real-life Experience from the HEPATHER ANRS CO22 Cohort - Sorbonne Université
Journal Articles Journal of Viral Hepatitis Year : 2020

Sofosbuvir-Daclatasvir Is Suboptimal in Patients with Genotype 2 Chronic Hepatitis C Infection: Real-life Experience from the HEPATHER ANRS CO22 Cohort

Fichier principal
Vignette du fichier
hal-03704126.pdf (431.09 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03704126 , version 1 (30-08-2022)

Identifiers

Cite

Victor Lédinghen, Clovis Lusivika-Nzinga, Jean-Pierre Bronowicki, Fabien Zoulim, Dominique Larrey, et al.. Sofosbuvir-Daclatasvir Is Suboptimal in Patients with Genotype 2 Chronic Hepatitis C Infection: Real-life Experience from the HEPATHER ANRS CO22 Cohort. Journal of Viral Hepatitis, 2020, 27 (10), pp.964--973. ⟨10.1111/jvh.13321⟩. ⟨hal-03704126⟩
112 View
101 Download

Altmetric

Share

More